# Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

> **NCT01565902** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** BAF312

## Key facts

- **NCT ID:** NCT01565902
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01565902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01565902, "Pharmacokinetics of BAF312 in Patients With Hepatic Impairment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01565902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*